AngioDynamics, Inc. ANGO
15.49
0.21
1.37%
as of 25 Sep
- Market cap
- $631.6M
- P/E
- 0.0×
Follow ANGO
Insider Buys
alert about insiders buying in the last 12 month
| May '26 | Feb '26 | Nov '25 | Aug '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.42 | 1.51 | 1.75 | 1.43 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
25.96 | (151.94) | 115.60 | (27.06) | |
P/B ratio |
2.65 | 2.73 | 3.06 | 2.41 | |
Price to Tangible BV |
4.37 | 4.38 | 4.92 | 3.90 | |
EV/Sales |
1.42 | 1.56 | 1.80 | 1.49 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
146.97 | 110.06 | (98.55) | (57.35) | |
EV/FCF |
(138.33) | (214.05) | (42.07) | (28.49) | |
Quick Ratio |
1.37 | 1.26 | 1.20 | 1.19 | |
Current Ratio |
2.19 | 2.35 | 2.24 | 2.29 | |
Net Debt/EBITDA |
11.71 | 5.14 | 110.15 | 8.36 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.17 | 1.15 | 1.10 | 1.08 | |
Operating CF/Net income |
(1.53) | 0.38 | (0.73) | 1.46 | |
Capex/Depreciation |
(0.07) | (0.18) | (0.07) | (0.12) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
9.44% | 9.03% | 9.78% | 8.48% | |
Selling, General and Administrative Expense of Revenue |
47.79% | 48.65% | 46.41% | 53.74% | |
Intangible Assets out of Total Assets |
0.25 | 0.25 | 0.25 | 0.26 | |
Share Based Compensation of Revenue |
4.52% | 3.42% | 3.64% | 5.90% | |
Graham Net Nets |
0.15 | 0.14 | 0.13 | 0.16 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(7.97%) | (6.60%) | (5.17%) | (7.46%) | |
Free Cash Flow Yield |
(0.72%) | (0.48%) | (2.43%) | (3.64%) | |
Revenue per Share |
2.09 | 1.89 | 1.91 | 1.84 | |
Operating CF per Share |
0.42 | (0.07) | 0.11 | (0.39) | |
Capex per Share |
(0.01) | (0.02) | (0.01) | (0.02) | |
Free Cash Flow per Share |
0.41 | (0.10) | 0.10 | (0.40) | |
Cash per Share |
1.30 | 0.91 | 1.00 | 0.94 | |
Shareholders Equity per Share |
4.11 | 4.17 | 4.24 | 4.34 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.11 | 4.17 | 4.24 | 4.34 | |
Free Cash Flow |
17.04 | (4.12) | 4.24 | (16.64) | |
Working Capital |
88.68 | 89.49 | 89.39 | 88.37 | |
Capital Expenditures |
(0.41) | (1.01) | (0.42) | (0.73) | |
Net Current Asset Value |
67.06 | 68.23 | 68.00 | 69.87 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.01 | |
Net Profit Margin |
(13.17%) | (10.31%) | (7.99%) | (14.40%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
45.61 | 47.26 | 43.80 | 41.10 | |
Average Payables |
32.40 | 29.69 | 35.07 | 31.58 | |
Average Inventory |
57.22 | 60.84 | 65.74 | 63.48 | |
Average Assets |
273.65 | 273.05 | 280.62 | 279.64 | |
Average Common Equity |
176.90 | 179.61 | 181.55 | 187.72 |
Columns are period end dates